Form 4: ANI Pharmaceuticals SVP Chad Gassert Sells 20,000 Shares

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock at a weighted average price of $64.41 on June 3, 2024, according to a Form 4 filing.

Summary

• Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on June 3, 2024.
• The shares were sold at a weighted average price of $64.41, with individual sales prices ranging from $63.35 to $65.40.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2023.
• Following the transaction, Gassert directly owns 49,679 shares and indirectly owns 213,226 shares through Chali Properties LLC.
• Gassert has voting and dispositive power over the shares held by Chali Properties LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a factual disclosure.

Industry Context

Insider sales are a common occurrence and are often viewed in the context of the individual's personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates